Trial Profile

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sipuleucel-T (Primary)
Indications Prostate cancer
Focus Adverse reactions
Acronyms PROCEED
Sponsors Dendreon Corporation

Most Recent Events

24 Jul 2021 Results of assessing the analysis of circulating immune biomarkers among racial subgroups of Black and white men with metastatic castration-resistant prostate cancer treated with sipuleucel-t, published in the Journal of the National Cancer Institute.
22 Jun 2021 Planned number of patients changed from 1500 to 1900.
12 Mar 2020 According to an Dendreon Pharmaceuticals media release, data from this study were published online in Prostate Cancer and Prostatic Diseases (PCAN), a peer-reviewed Nature Research journal.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com